Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May 28;15(6):3887-904.
doi: 10.3390/molecules15063887.

Synthesis and adrenolytic activity of new propanolamines

Grazyna Groszek  1 , Agata Bajek, Agnieszka Bis, Agnieszka Nowak-Król, Marek Bednarski, Agata Siwek, Barbara Filipek
Affiliations

Synthesis and adrenolytic activity of new propanolamines

Grazyna Groszek et al. Molecules. .

Abstract

The synthesis of (2R,S)-1-(6-methoxy-4-(methoxymethyl)-1H-indol-5-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol and (2R,S)-1-(4-methoxy-6-(methoxymethyl)-1H-indol-5-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol is described. The compounds were tested for electrographic, antiarrhythmic, hypotensive, and spasmolytic activity, as well as for alpha(1)-, alpha(2)- and beta(1)-adrenoceptor binding affinity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structure of the compound (R,S)-9.
Figure 2
Figure 2
Synthetic pathway.
Figure 3
Figure 3
Changes in mean blood pressure after iv administration of the tested compounds in the lowest effective doses.
Figure 4
Figure 4
Changes in mean blood pressure after po administration of the tested compounds in the lowest effective doses.
See this image and copyright information in PMC

References

    1. Groszek G., Bednarski M., Dybała M., Filipek B. Synthesis and adrenolytic activity of 1-(1H-indol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol and its enantiomers. Part 1. Eur. J. Med. Chem. 2009;44:809–817. doi: 10.1016/j.ejmech.2008.05.019. - DOI - PubMed
    1. Dulin B., Abraham W.T. Pharmacology of Carvedilol. Am. J. Cardiol. 2004;93:3–6. - PubMed
    1. Grassi G., Quarti-Trevano F., Seravalle G., Dell’Oro R. Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. Nutr. Metab. Cardiovasc. Dis. 2007;17:473–481. doi: 10.1016/j.numecd.2007.01.004. - DOI - PubMed
    1. Shannon R., Chaudhry M. Effect of α1-adrenergic receptors in cardiac pathophysiology. Am. Heart. J. 2006;152:842–850. doi: 10.1016/j.ahj.2006.05.017. - DOI - PubMed
    1. Kopecky S.L. Effect of Beta Blockers, Particularly Carvedilol, on Reducing the Risk of Events after Acute Myocardial Infarction. Am. J. Cardiol. 2006;98:1115–1119. doi: 10.1016/j.amjcard.2006.05.039. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources